DailyIQ
Last updatedUpdating…

CORT·Corcept Therapeutics Incorporated

$119.51
-0.06 (-0.05%)
After Hours
High
$122.00
Open
$119.00
Market Cap
13.07B
52W High
$126.38
Low
$117.23
P. Close
$119.51
P/E
236.90
52W Low
$28.66
Fwd P/E
27.50
DailyIQ Est.
$148.76
Inst. Ownership
0.4%
Short Interest
8.56%
Days to Cover
9.9
Technical Score (1D)
91
BULLISH
News Sentiment
45
MIXED
On Oct 6, Corcept Therapeutics’ stock fell during a broader medical sell‑off but stayed near buy‑level support, a move that analysts described as a short‑term correction rather than a fundamental shift. The same day, analysts highlighted concerns over the company’s declining earnings per share, noting a 16.1 % annual drop over five years, and cautioned that the recent 201 % price rally may not reflect sustainable fundamentals. On Oct 1, 2026, Corcept president Sean Maduck sold 25,000 shares for $2,906,601, leaving him with 119,655 shares under control; the filing indicated the transaction was a routine share liquidity move with no material effect on the company. Also on Oct 1, chief accounting officer Joseph Douglas Lyon sold 10,000 shares for $1,160,731, retaining 5,683 shares directly, and the filing stated the sale did not alter the company’s ownership dynamics. Together, the insider sales and the market reaction on Oct 6 suggest routine corporate activity and a short‑term market adjustment rather than a change in Corcept’s long‑term prospects.
LOW TARGET
$50 -58.2%
1 analysts
MEAN TARGET
$141 +17.9%
7 analysts
HIGH TARGET
$165 +38.0%
5 analysts
PRICE RANGE
$50.00 - $165.00
SB / B / H / S / SS
3/7/1/1/1
DAILYIQ EST.
$148.76 (+24.4%)
Bought (1Y)
0 shares
$0
Sold (1Y)
802,858 shares
$79.7M
Maduck SeanSee Remarks
Option Exercise24,587 shares2026-10-02
Maduck SeanSee Remarks
Sell8,744 shares2026-10-02
Maduck SeanSee Remarks
Sell15,843 shares2026-10-02
Maduck SeanSee Remarks
Option Exercise24,587 shares2026-10-02
Lyon Joseph DouglasSee Remarks
Option Exercise5,833 shares2026-10-02
82/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
98.3%
Net Margin
13.1%
Revenue CAGR
106.9%
Current Ratio
2.92x
Return on Equity
15.4%

EPS

EstBeatMiss
$0.03$0.26$0.50$0.74$0.97Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.86 - -
Q3'25$0.14$0.16+18.5%

Revenue

EstBeatMiss
$187M$231M$275M$319M$363MQ3'25Q3'26
QtrEstActual+/−
Q3'26$343M - -
Q3'25 - $208M -

Market Data

CORT Stock Snapshot

BULLISH91/100
$119.60+$0.09 (0.1%)
Market cap
13.07B
P/E ratio
236.9
Day range
$117.23 – $122.00
News sentiment
45/100 · Neutral
Analyst target
$141.00 (+17.9%)
Consensus
Buy · 13 analysts
52-week range+317.3% off low · -5.4% from high
$28.66$126.38
Price $119.60 DailyIQ Est. $148.76

Price is near its 52-week high, and the momentum read backs that positioning up. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What CORT's own history says about today's numbers

Realized volatility (21d)
38.6% 27th pct
Below its peak
-1.6%
vs 200-day average
+74.2%
Up days (1y)
53%

Corcept Therapeutics Incorporated is currently running 38.6% annualised volatility over the last 21 sessions. Measured against CORT's own 13 years of daily returns rather than a market-wide average, that is the 27th percentile — on the quiet side for this stock, against a typical reading of 49.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

CORT is trading -1.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -39.3%, and the deepest was -62.5% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +74.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 98th percentile — a wider gap than this stock usually carries. Over the past year CORT closed higher on 53% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, CORT finished the month higher 8 of 13 times, with a median return of +1.8% and an average of +1.5%. Its strongest month historically has been March at +10.1% on average, its weakest December at -6.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: CORT has opened more than 2% away from the prior close in 345 of 3,265 sessions (10.6% of the time), with the largest gaps running +17.2% and -32.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,267 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against CORT's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of CORT's sector?

Corcept Therapeutics Incorporated sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, CORT ranks 10th of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
64
Industry rank
#10 of 15

Options Market

What is the options market pricing for CORT?

CallsPuts

For Corcept Therapeutics Incorporated's nearest expiry (2026-10-16, 9 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.98), with at-the-money implied volatility around 68.3%. The options market is pricing roughly a ±9.7% move by that expiry — a range of about $103.57–$125.91.

Put/call ratio (2026-10-16)
0.98
ATM implied volatility
68.3%
Total open interest
2,420
Expected move by 2026-10-16
±9.7% ($103.57–$125.91)

Analyst Rating Changes

Are analysts turning bullish or bearish on CORT?

HC Wainwright & Co. most recently reiterated its rating on Corcept Therapeutics Incorporated to Buy on Sep 18, 2026 with a price target of $165. Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.

Latest action
HC Wainwright & Co. — Buy
90-day upgrades
0
90-day downgrades
1
Net rating momentum
-1
DateFirmActionRatingPrice target
Sep 18, 2026HC Wainwright & Co.ReiteratedBuy$165
Jul 30, 2026Piper SandlerReiteratedOverweight$88 → $165
Jul 30, 2026Canaccord GenuityMaintainedBuy$150 → $161
Jul 30, 2026HC Wainwright & Co.MaintainedBuy$95 → $165
Jul 29, 2026Canaccord GenuityMaintainedBuy$135 → $150
Jul 27, 2026Wolfe ResearchDowngradePeer Perform → Underperform$50
May 28, 2026Canaccord GenuityMaintainedBuy$110 → $135
May 28, 2026HC Wainwright & Co.MaintainedBuy$75 → $95
May 13, 2026UBSUpgradeNeutral → Buy$44 → $72
May 4, 2026HC Wainwright & Co.MaintainedBuy$60 → $75
May 1, 2026Piper SandlerMaintainedOverweight$73 → $88
Mar 26, 2026Canaccord GenuityMaintainedBuy$100 → $110

News Sentiment Analysis

Sentiment gathered from recent headlines

45/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Corcept Therapeutics’ stock fell on Oct. 6 during a broader medical sell‑off, but the decline was limited to near buy‑level support. The company’s earnings growth was highlighted as robust, suggesting underlying strength. The market reaction appeared to be a short‑term correction rather than a fundamental shift in the company’s prospects.
What did this article say?
On October 6, analysts highlighted concerns over Corcept’s declining earnings per share, noting a 16.1% annual drop over five years. The company’s stock had surged 201% in the past six months, yet the analysis suggested that the recent price rally may not reflect sustainable fundamentals. The report cautioned investors to exercise caution, presenting three reasons to consider selling CORT and recommending an alternative stock. The commentary emphasized that the EPS trend signals potential long‑term profitability issues, which could weigh on future valuation.
What did this article say?
On October 1, 2026, Corcept Therapeutics president Sean Maduck sold 25,000 shares of CORT for $2,906,601, reducing his direct holdings but leaving him with 119,655 shares under control. The transaction was filed as a Form 4 with the SEC and does not alter the company’s overall ownership structure. The sale reflects routine share liquidity for the insider and carries no immediate impact on CORT’s financial outlook.
What did this article say?
On October 1, 2026, Corcept Therapeutics chief accounting officer Joseph Douglas Lyon sold 10,000 shares of CORT for $1,160,731, as reported in a Form 4 filing. Lyon’s holdings remain at 5,683 shares, all held directly, and the sale does not change the company’s ownership dynamics. The transaction is a routine insider sale with no discernible effect on CORT’s operations or valuation.
What did this article say?
The article highlighted Corcept Therapeutics (CORT) as one of four low‑beta healthcare stocks suitable for investors wary of further Federal Reserve rate hikes. It noted that the September FOMC meeting raised rates to 3.75%‑4%, increasing market volatility and prompting a defensive tilt toward healthcare names. The piece emphasized that low‑beta stocks like CORT could provide stability in a high‑inflation environment. No specific guidance or earnings data for CORT were disclosed, and the recommendation was framed as a general sector strategy rather than a company‑specific forecast.
What did this article say?
The article compares the year‑to‑date performance of Corcept Therapeutics (CORT) with that of Aspen Pharmacare (APNHY). It notes that CORT is included in the same medical sector ranking as APNHY but does not report any new guidance, earnings, or material events for either company. The comparison focuses on sector rankings and analyst sentiment, with no indication of a significant change in outlook for CORT.
What did this article say?
Corcept Therapeutics released a second‑quarter investor letter highlighting robust commercial performance and expanding pipeline opportunities. The company reported solid sales growth driven by its flagship product portfolio and noted progress on several late‑stage development candidates targeting endocrine and metabolic disorders. Management emphasized strategic partnerships and a clear commercialization roadmap, reinforcing confidence in future revenue streams. The letter’s positive tone and concrete milestones suggest a material upside for the company’s valuation.
What did this article say?
Corcept Therapeutics (CORT) announced the retirement of Sean Maduck, President of its Endocrinology division, and the appointment of Justin Gunn to succeed him. The transition is scheduled to take effect in October, with Gunn assuming full responsibilities. The change is a routine leadership shuffle and does not signal any immediate operational or financial impact on the company.
What did this article say?
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has endorsed the combination of relacorilant and nab-paclitaxel for platinum‑resistant ovarian cancer, following encouraging Phase 2 and Phase 3 ROSELLA data. This regulatory backing confirms the clinical promise of CORT’s flagship therapy and is expected to lift investor confidence. The approval is likely to accelerate commercialization plans and could broaden the company’s oncology portfolio, reinforcing its undervalued status relative to peers.
What did this article say?
Corcept Therapeutics (CORT) received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for its relacorilant (Lifyorli) in combination with nab‑paclitaxel for platinum‑resistant ovarian cancer. The CHMP opinion follows a successful Phase 3 ROSELLA trial and is widely viewed as the final hurdle before formal European approval. This milestone positions CORT to expand its oncology portfolio into a new market, potentially driving revenue growth and enhancing its drug pipeline credibility.

Technical Analysis

Real-time indicators across multiple timeframes

91
BULLISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $37.02M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold425,7050.39%$37.02M2026-09-02
Q2 2026 flow:425.7K sh bought ($37.02M)0 sh sold ($0)net +425.7K sh (+$37.02M)